Virginia Beach, VA, United States
Walter Whitley, OD, MBA, FAAO serves as the Director of Professional Relations and Education for Virginia Eye Consultants in Norfolk, VA and Regional Medical Director for Eyecare Partners where his practice encompasses ocular surface disease, glaucoma, surgical co-management and clinical research. Dr. Whitley is a nationally recognized author and lecturer on a variety of topics ranging from ocular disease, surgical co-management, pharmaceuticals and practice management topics. He serves as co-chief medical editor for Modern Optometry, contributing editor for the Review of Optometry and co-medical editor for Dry Eye Coach. Dr. Whitley is the Immediate Past Chair of the American Academy of Optometry Anterior Segment Section and the immediate past president of the Virginia Optometric Association where he has been recognized as the 2012 Young Optometrist of the Year, the 2015 Legislative Keyperson of the Year and the 2020 Optometrist of the Year.
62 - Special Session - The Tried, The True, & The New in Ocular Surface Disease
Friday, February 27, 2026
9:00 AM - 11:00 AM EDT
Disclosure(s): AbbVie/Allergan: Advisory Committee/Board Member (), Consulting Fees (); Alcon: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Aldeyra Therapeutics: Consulting Fees (); Apellis Pharmaceuticals: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bausch + Lomb: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bruder: Advisory Committee/Board Member (); Dompe: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Epion: Advisory Committee/Board Member (); Glaukos: Consulting Fees (); Harrow Pharmaceuticals: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); I2-Vision, Inc: Advisory Committee/Board Member (), Consulting Fees (); Iveric: Consulting Fees (); Lenz: Speaker's Bureau (honoraria or other compensation) (); Mediprint Pharma: Consulting Fees (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Nordic Pharma: Consulting Fees (); Regener-Eyes: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Science Based Health: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Sight Sciences: Consulting Fees (); Sun Pharma: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Tarsus Pharma: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Trukera: Advisory Committee/Board Member (); Viatris: Consulting Fees (); Visus Therapeutics: Advisory Committee/Board Member ()
Friday, February 27, 2026
11:00 AM - 1:00 PM EDT
Disclosure(s): AbbVie/Allergan: Advisory Committee/Board Member (), Consulting Fees (); Alcon: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Aldeyra Therapeutics: Consulting Fees (); Apellis Pharmaceuticals: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bausch + Lomb: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bruder: Advisory Committee/Board Member (); Dompe: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Epion: Advisory Committee/Board Member (); Glaukos: Consulting Fees (); Harrow Pharmaceuticals: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); I2-Vision, Inc: Advisory Committee/Board Member (), Consulting Fees (); Iveric: Consulting Fees (); Lenz: Speaker's Bureau (honoraria or other compensation) (); Mediprint Pharma: Consulting Fees (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Nordic Pharma: Consulting Fees (); Regener-Eyes: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Science Based Health: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Sight Sciences: Consulting Fees (); Sun Pharma: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Tarsus Pharma: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Trukera: Advisory Committee/Board Member (); Viatris: Consulting Fees (); Visus Therapeutics: Advisory Committee/Board Member ()
119 - Lightning Rounds: Real Cases, Quick Calls
Friday, February 27, 2026
2:00 PM - 4:00 PM EDT
Disclosure(s): AbbVie/Allergan: Advisory Committee/Board Member (), Consulting Fees (); Alcon: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Aldeyra Therapeutics: Consulting Fees (); Apellis Pharmaceuticals: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bausch + Lomb: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bruder: Advisory Committee/Board Member (); Dompe: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Epion: Advisory Committee/Board Member (); Glaukos: Consulting Fees (); Harrow Pharmaceuticals: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); I2-Vision, Inc: Advisory Committee/Board Member (), Consulting Fees (); Iveric: Consulting Fees (); Lenz: Speaker's Bureau (honoraria or other compensation) (); Mediprint Pharma: Consulting Fees (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Nordic Pharma: Consulting Fees (); Regener-Eyes: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Science Based Health: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Sight Sciences: Consulting Fees (); Sun Pharma: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Tarsus Pharma: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Trukera: Advisory Committee/Board Member (); Viatris: Consulting Fees (); Visus Therapeutics: Advisory Committee/Board Member ()
Saturday, February 28, 2026
7:00 AM - 8:00 AM EDT
Disclosure(s): AbbVie/Allergan: Advisory Committee/Board Member (), Consulting Fees (); Alcon: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Aldeyra Therapeutics: Consulting Fees (); Apellis Pharmaceuticals: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bausch + Lomb: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bruder: Advisory Committee/Board Member (); Dompe: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Epion: Advisory Committee/Board Member (); Glaukos: Consulting Fees (); Harrow Pharmaceuticals: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); I2-Vision, Inc: Advisory Committee/Board Member (), Consulting Fees (); Iveric: Consulting Fees (); Lenz: Speaker's Bureau (honoraria or other compensation) (); Mediprint Pharma: Consulting Fees (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Nordic Pharma: Consulting Fees (); Regener-Eyes: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Science Based Health: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Sight Sciences: Consulting Fees (); Sun Pharma: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Tarsus Pharma: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Trukera: Advisory Committee/Board Member (); Viatris: Consulting Fees (); Visus Therapeutics: Advisory Committee/Board Member ()
138 - Clinical DEWS & Don'ts in Dry Eye
Saturday, February 28, 2026
2:00 PM - 3:00 PM EDT
Disclosure(s): AbbVie/Allergan: Advisory Committee/Board Member (), Consulting Fees (); Alcon: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Aldeyra Therapeutics: Consulting Fees (); Apellis Pharmaceuticals: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bausch + Lomb: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bruder: Advisory Committee/Board Member (); Dompe: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Epion: Advisory Committee/Board Member (); Glaukos: Consulting Fees (); Harrow Pharmaceuticals: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); I2-Vision, Inc: Advisory Committee/Board Member (), Consulting Fees (); Iveric: Consulting Fees (); Lenz: Speaker's Bureau (honoraria or other compensation) (); Mediprint Pharma: Consulting Fees (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Nordic Pharma: Consulting Fees (); Regener-Eyes: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Science Based Health: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Sight Sciences: Consulting Fees (); Sun Pharma: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Tarsus Pharma: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Trukera: Advisory Committee/Board Member (); Viatris: Consulting Fees (); Visus Therapeutics: Advisory Committee/Board Member ()